EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-GuérinSamantha Cambier, Jorg R. Oddens, Richard Sylvester et al.|European Urology|2015Cited by 639
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, S. Hafeez et al.|European Urology|2019Cited by 191
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines CommitteesAlan Horwich, Donna E. Hansel, Marek Babjuk et al.|Annals of Oncology|2019Cited by 182
Neutrophil percentage-to-albumin Ratio Predicts Mortality in Bladder Cancer Patients Treated With Neoadjuvant Chemotherapy Followed By Radical CystectomyMatteo Ferro, Mihai Dorin Vartolomei, Dragoș-Florin Babă et al.|Future Science OA|2021Cited by 79
Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-upRossana Critelli, Alessio Naccarati, Francesca Fasanelli et al.|Oncotarget|2016Cited by 71